Datapoint: New Report Shows Impact of Zeposia, Skyrizi on IBD Markets
Gastroenterologists are favoring new biologic and small molecule drugs over traditional TNF inhibitors as first-line therapies for the treatment of inflammatory bowel diseases like Crohn’s and ulcerative colitis, according to a new analysis from Spherix Global Insights. Bristol Myers Squibb’s Zeposia has been most disruptive to AbbVie’s Humira, Spherix said. For the treatment of ulcerative colitis, Zeposia currently holds covered or better status for 83% of all insured lives under the pharmacy benefit, with 30% of lives having preferred access to the immune modulator. And while Spherix said most Crohn’s patients are ultimately prescribed Janssen’s TNF inhibitor Stelara, AbbVie’s Skyrizi is shaking up the status quo. For the treatment of Crohn’s disease, Skyrizi holds covered or better status for 65% of all insured lives, with 15% having preferred access to the biologic.
SOURCE: MMIT Analytics, as of 12/12/22